Cargando…
Identification of key genes and specific pathways potentially involved in androgen-independent, mitoxantrone-resistant prostate cancer
BACKGROUND: Resistance to mitoxantrone (MTX), an anthracenedione antineoplastic agent used in advanced and metastatic androgen-refractory prostate cancer (PCa), seriously limits therapeutic success. METHODS: Xenografts from two human PCa cell lines (VCaP and CWR22) were established in male severe co...
Autores principales: | Zhu, Sha, Jiang, Lili, Wang, Liuyan, Wang, Lingli, Zhang, Cong, Ma, Yu, Huang, Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322516/ https://www.ncbi.nlm.nih.gov/pubmed/30655694 http://dx.doi.org/10.2147/CMAR.S179467 |
Ejemplares similares
-
Transcriptome analysis of differentially expressed genes and pathways associated with mitoxantrone treatment prostate cancer
por: Li, Sanqiang, et al.
Publicado: (2018) -
Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
por: Crona, Daniel J., et al.
Publicado: (2017) -
Mechanisms of Androgen-Independent Prostate Cancer
por: Saraon, Punit, et al.
Publicado: (2014) -
Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer
por: Xu, Lingfan, et al.
Publicado: (2019) -
Independence of HIF1a and androgen signaling pathways in prostate cancer
por: Tran, Maxine G. B., et al.
Publicado: (2020)